Volume 16, Number 10—October 2010
Dispatch
Artesunate Misuse and Plasmodium falciparum Malaria in Traveler Returning from Africa
Table
Strain |
Pfmdr1 |
PfATPase |
pfmdr1 copy no. |
CQ IC50, nmol/L |
MQ IC50, nmol/L |
ART IC50, nmol/L |
||||||
86 |
184 |
1034 |
1042 |
1246 |
623 |
769 |
||||||
3D7 | N | Y | S | N | D | A | S | 1.00 | 6.1 | 2.1 | 6.1 | |
W2 | Y | Y | S | N | D | A | S | 0.97 | 252 | 3.2 | 7.3 | |
Cameroon | Y | F | S | N | D | E | N | 1.85 | 163 | 7.7 | 8.07 | |
Congo | Y | F | S | N | D | E | N | 1.51 | 355 | 10.7 | 10.9 | |
Kenya | Y | F | S | N | D | E | N | 1.75 | 282 | 11.7 | 10.1 | |
Liberia | N | F | S | N | D | E | N | 1.65 | 109 | 16.2 | 16.5 | |
Nigeria C | Y | F | S | N | D | E | N | 1.06 | 222 | 8.7 | 8.1 | |
Nigeria A | N | F | S | N | D | E | N | 1.52 | 171 | 16.6 | 20.1 | |
Nigeria B | Y | F | S | N | D | E | N | 1.09 | 188 | 5.6 | 10.0 | |
Ghana | N | F | S | N | D | E | N | 0.96 | 24.0 | 11.6 | 14.2 | |
Tanzania | Y | F | S | N | Y | E | N | 1.88 | 381 | 7.8 | 16.6 | |
Angola | Y | F | S | N | D | E | N | 0.81 | 258 | 4.5 | 7.3 |
* At Pfmdr1 and PfATPase6 residues previously implicated in artemisinin resistance and gene copy number of pfmdr1 by quantitative real-time PCR in relation to mean IC50 (n = 3) data for key drugs (7,8,10). pfmdr1, P. falciparum multidrug resistance 1; CQ, chloroquine; MQ, mefloquine; ART, artemisinin; IC50., 50% minimum inhibitory concentration; N, asparagine; Y, tyrosine; S, serine; D, aspartic acid; A, alanine; E, glutamic acid; 3D7, chloroquine-sensitive laboratory strain; W2, chloroquine-resistant laboratory strain; Nigeria A, clinical isolate described in this report.
References
- Centers for Disease Control and Prevention. Artesunate now available to treat severe malaria in the United States [cited 2010 Jun 10]. http://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html
- Centers for Disease Control and Prevention. Coartem, new malaria treatment drug, now available [cited 2010 Jun 10]. http://www.cdc.gov/malaria/diagnosis_treatment/treatment.html
- Health Canada. Special Access Programme—drugs [cited 2010 Jun 10]. http://www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index-eng.php
- Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67. DOIPubMedGoogle Scholar
- Bacaner N, Stauffer B, Boulware DR, Walker PF, Keystone JS. Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA. 2004;291:2856–64. DOIPubMedGoogle Scholar
- Johnson JD, Dennull RA, Gerena L, Lopez-Sanchez M, Roncal NE, Waters NC. Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Antimicrob Agents Chemother. 2007;51:1926–33. DOIPubMedGoogle Scholar
- Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ, The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother. 1999;43:2943–9.PubMedGoogle Scholar
- Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet. 2005;366:1960–3. DOIPubMedGoogle Scholar
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real- time quantitative PCR and the 2–-∆∆CT method. Methods. 2001;25:402–8. DOIPubMedGoogle Scholar
- Imwong M, Dondorp AM, Nosten F, Yi P, Mungthin M, Hanchana S, Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother. 2010;54:2886–92. DOIPubMedGoogle Scholar
- Chavchich M, Gerena L, Peters J, Chen N, Cheng Q, Kyle DE. Role of pfmdr1 amplification and expression in induction of resistance to artemisinin derivatives in Plasmodium falciparum. Antimicrob Agents Chemother. 2010;54:2455–64. DOIPubMedGoogle Scholar
- Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619–20. DOIPubMedGoogle Scholar
- Plowe CV, Roper C, Barnwell JW, Happi CT, Joshi HH, Mbacham W, World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J. 2007;6:121. DOIPubMedGoogle Scholar
Page created: September 07, 2011
Page updated: September 07, 2011
Page reviewed: September 07, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.